Agent-specific, histopathology-stratified hematologic malignancy risk among dpp-4 inhibitors, glp-1 receptor agonists, and SGLT2 inhibitors: a network meta-analysis of 270,471 participants
Authors:
Open Access
- 9 April 2026
- journal article
- review article
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 19 (1) , 23
Abstract
Dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and sodium–glucose cotransporter 2 (SGLT2) inhibitors are widely prescribed for their cardiometabolic benefits, yet their hematologic oncologic safety remains uncertain. Because hematologic malignancies are highly lethal and biologically heterogeneous, delineating drug-specific risks across histopathologic subtypes is clinically crucial. This histopathology-stratified network meta-analysis (NMA) evaluated and compared the hematologic malignancy risks associated with individual agents from these drug classes. Following Cochrane guidance for adverse-event synthesis, we conducted this frequentist-based NMA of randomized controlled trials (RCTs). The primary endpoint was incident hematologic malignancy, categorized a priori into leukemia (acute and chronic forms), lymphoma (Hodgkin and non-Hodgkin), and myeloma/plasma cell neoplasms. Bayesian models were used as sensitivity analyses. Seventy-five RCTs including 270,471 participants were eligible. Dulaglutide was associated with a significantly increased risk of overall hematologic malignancy (RR = 2.17, 95% CIs = 1.14–4.17). In contrast, tirzepatide (RR = 0.22, 95% CIs = 0.06–0.78) and linagliptin (RR = 0.51, 95% CIs = 0.27–0.95) were linked to a reduced overall risk. In histopathology-specific analyses, tirzepatide showed a significant protective association against non-Hodgkin’s lymphoma, whereas no agent demonstrated clear signals for leukemia or myeloma. In this histopathology-focused NMA, dulaglutide emerged as the only agent with a significantly elevated overall hematologic malignancy risk, whereas tirzepatide and linagliptin exhibited protective profiles. The lymphoma-specific benefit observed for tirzepatide underscores the value of histologic subclassification when evaluating oncologic safety of antidiabetic therapies and calls for targeted mechanistic and long-term outcome studies. Trial registration: PROSPERO CRD420251151419. The study protocol was approved by the Institutional Review Board of the Tri-Service General Hospital, National Defense Medical University (TSGHIRB E202516007).Keywords
Funding Information
- Tri-Service General Hospital Beitou Branch (TSGH-BT-X-115006)
This publication has 11 references indexed in Scilit:
- Divergent Risks of Hematologic Malignancies Associated with GLP-1 Receptor Agonists and SGLT2 Inhibitors: Preliminary Findings from a Pilot Network Meta-AnalysisBiomolecules, 2025
- Adverse Events in Studies of Classic PsychedelicsJAMA Psychiatry, 2024
- Tirzepatide as an innovative treatment strategy in a pre-clinical model of obesity-driven endometrial cancerGynecologic Oncology, 2024
- Disparities in mortality risk after diagnosis of hematological malignancies in 185 countries: A global data analysisCancer Letters, 2024
- The application of lag times in cancer pharmacoepidemiology: a narrative reviewAnnals of Epidemiology, 2023
- Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysisThe Lancet Psychiatry, 2020
- Network Meta-analysisThe Stata Journal: Promoting communications on statistics and Stata, 2015
- Evaluating the Quality of Evidence from a Network Meta-AnalysisValue in Health, 2014
- ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer TherapeuticsCancer Cell, 2014
- Structure of the Extracellular Region of HER3 Reveals an Interdomain TetherScience, 2002